Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’
The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.
You may also be interested in...
Demonstration would ‘build on’ Medicare price controls established by the Inflation Reduction Act, White House says.
Latest iteration of drug pricing legislation from Senate Democrats would also firm up the number of drugs HHS must choose for price negotiation each year and no longer treats insulin as a separate class for purposes of negotiation.
Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.